DESTINY-BREAST05

A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd)  versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy. (T-DXd vs. T-DM1 in high-risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy)

Die Studie eignet sich für:
Patienten mit einem HER2-Positiven primären Brustkrebs mit Resterkrankung nach der präoperativen Therapie